{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:29:40Z","timestamp":1761092980178,"version":"build-2065373602"},"reference-count":46,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":1284,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:p>Angiotensin\u2010converting enzyme (ACE) inhibitors and \u03b2\u2010blockers make up the cornerstone of therapy for patients with heart failure involving left ventricular dysfunction. These drug classes have been proven to decrease morbidity and mortality in patients with heart failure. Unfortunately, many patients remain symptomatic and experience disease progression despite taking both an ACE inhibitor and a \u03b2\u2010blocker. Others may be unable to tolerate one or both of these agents. In recent years, several other drug classes have been shown to provide additional morbidity and mortality benefits in patients with heart failure. These include angiotensin II receptor blockers (ARBs), aldosterone antagonists, and the combination of isosorbide dinitrate plus hydralazine. To select the most appropriate drug therapy for patients with heart failure, clinicians should consider results from clinical trials in specific patient populations, adverse\u2010event profiles, tolerability, cost, and dosing regimens.<\/jats:p>","DOI":"10.1592\/phco.28.7.920","type":"journal-article","created":{"date-parts":[[2008,6,24]],"date-time":"2008-06-24T11:47:08Z","timestamp":1214308028000},"page":"920-931","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacotherapy for Heart Failure with Left Ventricular Dysfunction: Beyond Angiotensin\u2010Converting Enzyme Inhibitors and \u03b2\u2010Blockers"],"prefix":"10.1002","volume":"28","author":[{"given":"Nicholas B.","family":"Norgard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer E.","family":"Stark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-005-6900-8"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.3317\/jraas.2000.030"},{"key":"e_1_2_1_4_2","first-page":"PE16","article-title":"Angiotensin type 2 receptor (AT2R): a challenging twin","volume":"181","author":"Berk BC","year":"2003","journal-title":"Sci STKE"},{"issue":"3","key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","article-title":"The angiotensin II receptors","volume":"52","author":"Gasparo M","year":"2000","journal-title":"Pharmacol Rev"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.141.10.7711"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0039-128X(94)00030-G"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.83.6.1849"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1006\/jmcc.1993.1066"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-9164(96)80009-1"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.10.1056"},{"issue":"8","key":"e_1_2_1_12_2","first-page":"803","article-title":"Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?","volume":"10","author":"Meiracker AH","year":"1992","journal-title":"J Hypertens"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.82.5.1730"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(99)00103-X"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198912000-00001"},{"issue":"4","key":"e_1_2_1_16_2","first-page":"H1769","article-title":"Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations","volume":"273","author":"Balcells E","year":"1997","journal-title":"Am J Physiol"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000074041.81728.79"},{"issue":"1","key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/euhj.1999.1740","article-title":"Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure","volume":"21","author":"Roig E","year":"2000","journal-title":"Eur Heart J"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119360"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02213-3"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00898-4"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032292"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000129331.21092.1d"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010713"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14283-3"},{"issue":"5","key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The SOLVD Investigators.","year":"1991","journal-title":"N Eng J Med"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.02.028"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.18.1930"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(03)00477-9"},{"issue":"12","key":"e_1_2_1_30_2","first-page":"e154","article-title":"ACC\/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American college of cardiology\/American heart association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American college of chest physicians and the international society for heart and lung transplantation: endorsed by the heart rhythm society [online exclusive article]","volume":"112","author":"Hunt S","year":"2005","journal-title":"Circulation"},{"issue":"1","key":"e_1_2_1_31_2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2005.11.005","article-title":"HFSA 2006 comprehensive heart failure practice guideline [online exclusive article]","volume":"12","author":"Heart Failure Society of America.","year":"2006","journal-title":"J Card Fail"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.63.3.645"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00795367"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.27.5.1039"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030207"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040135"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.527549"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(03)00189-3"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000126497.38281.23"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.12.1291"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-9164(99)90001-5"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198606123142404"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250502"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042934"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(92)90986-6"},{"key":"e_1_2_1_47_2","unstructured":"Drugstore.com.Pricing information. Available fromhttp:www.drugstore.com. Accessed June 18 2007."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.28.7.920","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.28.7.920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:47:34Z","timestamp":1761040054000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.28.7.920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1592\/phco.28.7.920"],"URL":"https:\/\/doi.org\/10.1592\/phco.28.7.920","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2008,7]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}